Integral Health Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Integral Health Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.1M	Hold	200,000	–	–	0.48%	55
2026 Q1	$11.6M	Buy	+200,000	New	+$9.22M	0.56%	47
2022 Q3	–	Sell	-97,281	Closed	-$2.96M	–	78
2022 Q2	$2.96M	Buy	+97,281	New	+$2.94M	0.61%	51

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Integral Health Asset Management's XENE Position: Q2 2026 in Review

Integral Health Asset Management held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 200,000 shares worth $12.1M. The position accounts for 0.48% of the portfolio, ranked #55.

Integral Health Asset Management first reported a position in XENE in Q2 2022 and has held it in 3 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Integral Health Asset Management held 200,000 shares of Xenon Pharmaceuticals worth $12.1M as of Q2 2026.
Integral Health Asset Management left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up 0.48% of Integral Health Asset Management's portfolio in Q2 2026, its #55 holding.
Integral Health Asset Management first reported a position in Xenon Pharmaceuticals in Q2 2022 and has held it in 3 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.